opnurasib
novartis
['jdq443', 'sclc', 'nsclc']
jdq443 in kras g12c nsclc by dr. de miguel. orr 57.1% at 200 mg bid (recommended expansion dose) and 44.4% at all dose levels. several ongoing combination trials. #asco23 
Thoracic Medical Oncologist at Georgetown University | Father/husband/immigrant | #SoMeEditor @ClinicalLung | #LCSM